The stock's fall snapped a three-day winning streak.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), ...

This was the stock's third consecutive day of gains.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer recently talked about. The Federal Reserve ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...

H.C. Wainwright has recently reiterated Vertex Pharmaceuticals Inc (VRTX) stock to Buy rating, as announced on Today, according to Finviz. Earlier, on December 19, 2024, Oppenheimer had reduced the ...

NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") ...

Vertex Pharmaceuticals (NASDAQ:VRTX) faces a potential downside in its stock price, as indicated by RBC Capital’s price target. The company’s stock experienced a significant decline following ...